Summary
Background
Methods
Results
Conclusions
Keywords
1. Introduction
World Health Organization. Global tuberculosis control 2010. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html (accessed November 2011).
World Health Organization Eastern Mediterranean Region. Country profile 2008–2009: Tunisia. Egypt: WHO EMRO; 2010. Available at: http://www.emro.who.int/stb/pdf/CountryProfile-tun-08.pdf (accessed September 2010).
2. Materials and methods
2.1 Studied populations
2.1.1 Patients with tuberculosis
2.1.2 Controls
2.2 DNA extraction
2.3 NRAMP1 genotyping


2.4 Statistical analysis
3. Results
3.1 Hardy–Weinberg equilibrium
3.2 Associations of NRAMP1 D543N with TB susceptibility
PTB + EPTB (n = 223) | Controls (n = 150) | p-Value (pc) | OR (95% CI) | |
---|---|---|---|---|
D543N | ||||
Genotype | ||||
AA | 10 (5) | 1 (1) | 0.02 (NS) | 7 (0.91–147.61) |
AG | 70 (31) | 34 (23) | 0.06 (NS) | 1.56 (0.95–2.58) |
GG | 143 (64) | 115 (76) | 0.01 (0.03) | 0.54 (0.33–0.89) |
Allele | ||||
A | 90 (20) | 36 (12) | 0.003 | 1.85 (1.2–2.88) |
G | 356 (80) | 264 (88) | ||
3′-UTR | ||||
Genotype | ||||
del/del | 102 (46) | 68 (46) | 0.93 (NS) | 1.02 (0.66–1.57) |
TGTG+/del | 88 (39) | 62 (41) | 0.71 (NS) | 0.93 (0.59–1.44) |
TGTG+/+ | 33 (15) | 20 (13) | 0.69 (NS) | 1.13 (0.6–2.14) |
Allele | ||||
del | 292 (65) | 198 (66) | 0.88 | 0.98 (0.71–1.35) |
TGTG+ | 154 (35) | 102 (34) |
PTB (n= 168) | Controls (n= 150) | p-Value (pc) | OR (95% CI) | p-Value (pc) | OR (95% CI) | p-Value (pc) | OR (95% CI) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
M+F (%) | M (%) | F (%) | M+F (%) | M (%) | F (%) | |||||||
D543N | ||||||||||||
Genotype | ||||||||||||
AA | 10 (6) | 7 (6) | 3 (7) | 1 (1) | 1 (1) | 0 (0) | 0.01 (0.03) | 9.43 (1.22–199.3) | 0.02 (NS) | 7.82 (0.95–171.49) | 0.38 (NS) | ND |
AG | 50 (30) | 14 (11) | 36 (88) | 34 (23) | 24 (18) | 10 (67) | 0.15 (NS) | 1.45 (0.85–2.47) | 0.16 (NS) | 0.61 (0.28–1.3) | 0.07 (NS) | 3.6 (0.71–18.75) |
GG | 108 (64) | 106 (83) | 2 (5) | 115 (76) | 110 (81) | 5 (33) | 0.01 (0.03) | 0.55 (0.32–0.92) | 0.67 (NS) | 1.15 (0.58–2.28) | 0.01 (0.03) | 0.1 (0.01–0.74) |
Allele | ||||||||||||
A | 70 (21) | 28 (11) | 42 (51) | 36 (12) | 26 (10) | 10 (33) | 0.002 | 1.93 (1.22–3.06) | 0.59 | 1.16 (0.64–2.12) | 0.09 | 2.1 (0.81–5.53) |
G | 266 (79) | 226 (89) | 40 (49) | 264 (88) | 244 (90) | 20 (67) | ||||||
3′-UTR | ||||||||||||
Genotype | ||||||||||||
del/del | 80 (48) | 60 (47) | 20 (49) | 68 (46) | 63 (47) | 5 (34) | 0.68 (NS) | (0.69–1.75) | 0.92 (NS) | 1.02 (0.61–1.71) | 0.3 (NS) | 1.9 (0.48–7.86) |
TGTG+/del | 67 (40) | 52 (41) | 15 (36) | 62 (41) | 54 (40) | 8 (53) | 0.79 (NS) | 0.94 (0.59–1.51) | 0.87 (NS) | 1.04 (0.62–1.76) | 0.25 (NS) | 0.5 (0.13–1.95) |
TGTG+/+ | 21 (12) | 15 (12) | 6 (15) | 20 (13) | 18 (13) | 2 (13) | 0.82 (NS) | 0.93 (0.46–1.88) | 0.71 (NS) | 0.87 (0.39–1.92) | 0.63 (NS) | 1.11 (0.17–9.2) |
Allele | ||||||||||||
del | 227 (68) | 172 (68) | 55 (67) | 198 (66) | 180 (67) | 18 (60) | 0.67 | 1.07 (0.76–1.51) | 0.79 | 1.05 (0.72–1.54) | 0.48 | 1.36 (0.52–3.5) |
TGTG+ | 109 (32) | 82 (32) | 27 (33) | 102 (34) | 90 (33) | 12 (40) |
EPTB (n = 55) | Controls (n = 150) | p-Value (pc) | OR (95% CI) | p-Value (pc) | OR (95% CI) | p-Value (pc) | OR (95% CI) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
M+F (%) | M (%) | F (%) | M+F (%) | M (%) | F (%) | |||||||
D543N | ||||||||||||
Genotype | ||||||||||||
AA | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 1 (1) | 0 (0) | 0.7 (NS) | 0 (0–47.94) | 0.8 (NS) | 0 (0–72.71) | ND | ND |
AG | 20 (36) | 1 (3) | 19 (86) | 34 (23) | 24 (18) | 10 (67) | 0.04 (NS) | 1.95 (0.95–4.01) | 0.02 (NS) | 0.14 (0.01–1.07) | 0.1 (NS) | 3.17 (0.5–21.81) |
GG | 35 (64) | 32 (97) | 3 (14) | 115 (76) | 110 (81) | 5 (33) | 0.06 (NS) | 0.53 (0.26–1.09) | 0.02 (NS) | 7.27 (0.98–149.64) | 0.1 (NS) | 0.32 (0.05–2.01) |
Allele | ||||||||||||
A | 20 (18) | 1 (2) | 19 (43) | 36 (12) | 26 (10) | 10 (33) | 0.1 | 1.63 (0.86–3.08) | 0.02 (NS) | 0.14 (0.01–1.03) | 0.3 | 1.52 (0.52–4.47) |
G | 90 (82) | 65 (98) | 25 (57) | 264 (88) | 244 (90) | 20 (67) | ||||||
3′-UTR | ||||||||||||
Genotype | ||||||||||||
del/del | 22 (40) | 12 (36) | 10 (46) | 68 (46) | 63 (47) | 5 (34) | 0.4 (NS) | 0.8 (0.41–1.58) | 0.2 (NS) | 0.65 (0.28–1.53 | 0.46 (NS) | 1.67 (0.35–8.14) |
TGTG+/del | 21 (38) | 15 (46) | 6 (27) | 62 (41) | 54 (40) | 8 (53) | 0.6 (NS) | 0.88 (0.44–1.73) | 0.56 (NS) | 1.25 (0.54–2.87) | 0.1 (NS) | 0.33 (0.06–1.59) |
TGTG+/+ | 12 (22) | 6 (18) | 6 (27) | 20 (13) | 18 (13) | 2 (13) | 0.1 (NS) | 1.81 (0.76–4.29) | 0.31 (NS) | 1.44 (0.46–4.35) | 0.27 (NS) | 2.44 (0.34–21.17) |
Allele | ||||||||||||
del | 65 (59) | 39 (59) | 26 (59) | 198 (66) | 180 (67) | 18 (60) | 0.1 | 0.74 (0.46–1.2) | 0.24 | 0.72 (0.4–1.3) | 0.93 | 0.96 (0.34–2.75) |
TGTG+ | 45 (41) | 27 (41) | 18 (41) | 102 (34) | 90 (33) | 12 (40) |
≤29 years | p-Value (pc) | OR (95% CI) | 30–49 years | p-Value (pc) | OR (95% CI) | ≥50 years | p-Value (pc) | OR (95% CI) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PTB (%) | Controls (%) | PTB (%) | Controls (%) | PTB (%) | Controls (%) | |||||||
D543N | ||||||||||||
Genotype | ||||||||||||
AA | 10 (12) | 1 (1) | 6.10−3 (18.10−3) | 10.8 (1.37–230.8) | 0 (0) | 0 (0) | ND | ND | 0 (0) | 0 (0) | ND | ND |
AG | 15 (18) | 17 (21) | 0.6 (NS) | 0.82 (0.35–1.89) | 25 (43) | 10 (22) | 0.02 (NS) | 2.65 (1.02–7) | 10 (40) | 7 (30) | 0.4 (NS) | 1.52 (0.39–5.98) |
GG | 60 (70) | 64 (78) | 0.2 (NS) | 0.68 (0.32–1.44) | 33 (57) | 35 (78) | 0.02 (NS) | 0.38 (0.14–0.98) | 15 (60) | 16 (70) | 0.4 (NS) | 0.66 (0.17–2.54) |
3′-UTR | ||||||||||||
Genotype | ||||||||||||
del/del | 30 (68) | 20 (36) | 10−3 (3.10−3) | 3.75 (1.5–9.52) | 20 (40) | 30 (57) | 0.09 (NS) | 0.51 (0.22–1.2) | 30 (41) | 18 (43) | 0.8 (NS) | 0.91 (0.39–2.1) |
TGTG+/del | 7 (16) | 25 (46) | 10−3 (3.10−3) | 0.23 (0.08–0.65) | 20 (40) | 15 (28) | 0.21 (NS) | 1.69 (0.69–4.18) | 40 (54) | 22 (52) | 0.8 (NS) | 1.07 (0.47–2.45) |
TGTG+/+ | 7 (16) | 10 (18) | 0.7 (NS) | 0.85 (0.26–2.74) | 10 (20) | 8 (15) | 0.86 (NS) | 1.09 (0.35–3.47) | 4 (5) | 2 (5) | 0.6 (NS) | 1.14 (0.17–9.46) |
≤29 years | p-Value (pc) | OR (95% CI) | 30–49 years | p-Value (pc) | OR (95% CI) | ≥50 years | p-Value (pc) | OR (95% CI) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
EPTB (%) | Controls (%) | EPTB (%) | Controls (%) | EPTB (%) | Controls (%) | |||||||
D543N | ||||||||||||
Genotype | ||||||||||||
AA | 0 (0) | 1 (1) | 0.7 (NS) | 0 (0–48.69) | 0 (0) | 0 (0) | ND | ND | 0 (0) | 0 (0) | ND | ND |
AG | 16 (53) | 17 (21) | 8.10−4 (24.10−4) | 4.37 (1.64–11.82) | 3 (19) | 10 (22) | 0.5 (NS) | 0.81 (0.15–3.98) | 1 (11) | 7 (30) | 0.2 (NS) | 0.29 (0.01–3.2) |
GG | 14 (47) | 64 (78) | 10−3 (3.10−3) | 0.25 (0.09–0.65) | 13 (81) | 35 (78) | 0.5 (NS) | 1.24 (0.25–6.76) | 8 (89) | 16 (70) | 0.2 (NS) | 3.5 (0.31–89.3) |
3′-UTR | ||||||||||||
Genotype | ||||||||||||
del/del | 7 (54) | 20 (36) | 0.2 (NS) | 2.04 (0.52–8.16) | 5 (28) | 30 (57) | 0.03 (NS) | 0.29 (0.08–1.07) | 10 (42) | 18 (43) | 0.9 (NS) | 0.95 (0.31–2.96) |
TGTG+/del | 2 (15) | 25 (45) | 0.04 (NS) | 0.22 (0.03–1.21) | 7 (39) | 15 (28) | 0.4 (NS) | 1.61 (0.46–5.67) | 12 (50) | 22 (52) | 0.8 (NS) | 0.91 (0.3–2.79) |
TGTG+/+ | 4 (31) | 10 (19) | 0.3 (NS) | 2 (0.42–9.32) | 6 (33) | 8 (15) | 0.09 (NS) | 2.81 (0.69–11.44) | 2 (8) | 2 (5) | 0.4 (NS) | 1.82 (0.17–19.84) |
3.3 Associations of NRAMP1 3′-UTR with TB susceptibility
3.4 NRAMP1 (D543N and 3′-UTR) haplotype and diplotype distributions
Controls (n = 150) (%) | PTB + EPTB (n= 223) (%) | p-Value (pc) | OR (95% CI) | PTB (n = 168) (%) | p-Value (pc) | OR (95% CI) | EPTB (n = 55) (%) | p-Value (pc) | OR (95% CI) | |
---|---|---|---|---|---|---|---|---|---|---|
Diplotype | ||||||||||
AA/deldel | 1 (1) | 10 (4) | 0.02 (NS) | 7 (0.91–147.61) | 10 (6) | 0.01 (NS) | 9.43 (1.22–199.29) | 0 (0) | 0.73 (NS) | 0 (0–47.94) |
AG/deldel | 30 (20) | 58 (26) | 0.18 (NS) | 1.41 (0.83–2.39) | 40 (24) | 0.41 (NS) | 1.25 (0.71–2.21) | 18 (33) | 0.05 (NS) | 1.95 (0.92–4.1) |
AG/TGTG+/+ | 4 (3) | 12 (5) | 0.2 (NS) | 2.08 (0.61–7.79) | 10 (6) | 0.15 (NS) | 2.31 (0.65–8.95) | 2 (4) | 0.51 (NS) | 1.38 (0.17–9.1) |
GG/deldel | 37 (25) | 34 (15) | 0.02 (NS) | 0.55 (0.32–0.95) | 30 (18) | 0.13 (NS) | 0.66 (0.37–1.18) | 4 (7) | 0.005 (0.03) | 0.24 (0.07–0.75) |
GG/TGTG+/del | 62 (41) | 88 (40) | 0.71 (NS) | 0.93 (0.59–1.44) | 67 (40) | 0.79 (NS) | 0.94 (0.59–1.51) | 21 (38) | 0.68 (NS) | 0.88 (0.44–1.73) |
GG/TGTG+/+ | 16 (10) | 21 (10) | 0.69 (NS) | 0.87 (0.42–1.82) | 11 (6) | 0.18 (NS) | 0.59 (0.24–1.39) | 10 (18) | 0.15 (NS) | 1.86 (0.72–4.74) |
Haplotype | ||||||||||
A-del | 33 (11) | 76 (17) | 0.02 (NS) | 1.66 (1.05–2.64) | 61 (18) | 0.01 (0.04) | 1.79 (1.11–2.9) | 20 (18) | 0.05 (NS) | 1.8 (0.94–3.42) |
G-del | 165 (55) | 214 (48) | 0.06 (NS) | 0.75 (0.56–1.02) | 168 (50) | 0.2 (NS) | 0.82 (0.59–1.13) | 47 (43) | 0.02 (NS) | 0.61 (0.38–0.97) |
A-TGTG+ | 3 (1) | 13 (3) | 0.07 (NS) | 2.97 (0.78–13.24) | 10 (3) | 0.07 (NS) | 3.04 (0.76–14.03) | 0 (0) | 0.39 (NS) | 0 (0–6.12) |
G-TGTG+ | 99 (33) | 143 (32) | 0.78 (NS) | 0.96 (0.69–1.33) | 97 (29) | 0.26 (NS) | 0.82 (0.58–1.17) | 43 (39) | 0.25 (NS) | 1.3 (0.81–2.1) |
4. Discussion
World Health Organization. Global tuberculosis control 2010. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html (accessed November 2011).
Acknowledgements
References
World Health Organization. Global tuberculosis control 2010. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html (accessed November 2011).
- Inborn errors of immunity to infection: the rule rather than the exception.J Exp Med. 2005; 202: 197-201
- Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae.Lancet Infect Dis. 2004; 4: 739-749
- Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis.Tuberculosis. 2010; 90: 71-73
- Tuberculosis in children and adults: two distinct genetic diseases.J Exp Med. 2005; 202: 1617-1621
- Genetic dissection of immunity to mycobacteria: the human model.Annu Rev Immunol. 2002; 20: 581-620
- Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases.Int J Infect Dis. 2011; 15: e305-e313
- Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae.Nat Genet. 2002; 32: 97-105
- IFN-γ +874T/A polymorphism is associated with susceptibility to active pulmonary tuberculosis development in Tunisian patients.DNA Cell Biol. 2011; 30: 379-387
- Molecular subtypes of the HLA-DR antigens in pulmonary tuberculosis.Int J Infect Dis. 2000; 4: 129-133
- Association of HLA-DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of South Africa.Hum Immunol. 2006; 67: 643-654
- Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population.Int J Infect Dis. 2010; 14: e84-e85
- Relationship between polymorphism of DC-SIGN (CD209) gene and the susceptibility to pulmonary tuberculosis in an eastern Chinese population.Hum Immunol. 2011; 72: 183-186
- Major histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in patients with pulmonary tuberculosis.Hum Immunol. 2011; 72: 173-178
- Susceptibility to mycobacterial infections: the importance of host genetics.Genes Immun. 2003; 4: 4-11
- SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: updated systematic review and meta-analysis.PLoS One. 2011; 6: e15831
- Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter.Biochem J. 2001; 354: 511-519
- Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome.J Exp Med. 1997; 185: 717-730
- From Bcg/Lsh/Ity to Nramp1: three decades of search and research.Drug Metab Dispos. 2001; 29: 471-473
- Genomic organization and sequence of the human NRAMP gene: identification and mapping of a promoter region polymorphism.Mol Med. 1995; 1: 194-205
- Human natural resistance-associated macrophage protein: cDNA cloning, chromosomal mapping, genomic organization, and tissue-specific expression.J Exp Med. 1994; 180: 1741-1752
- Identification of C to T mutation at position −236 bp in the human NRAMP1 gene promoter.Immunogenetics. 1996; 44: 309-311
- SLC11A1 (formerly NRAMP1) and disease resistance.Cell Microbiol. 2001; 3: 773-784
- Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans.N Engl J Med. 1998; 338: 640-644
- Variants of the human NRAMP1 gene and susceptibility to tuberculosis in Morocco.Int J Tuberc Lung Dis. 2003; 7: 599-602
- SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis.Int J Tuberc Lung Dis. 2006; 10: 3-12
- 3′UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans.Int J Tuberc Lung Dis. 2000; 4: 577-580
World Health Organization Eastern Mediterranean Region. Country profile 2008–2009: Tunisia. Egypt: WHO EMRO; 2010. Available at: http://www.emro.who.int/stb/pdf/CountryProfile-tun-08.pdf (accessed September 2010).
- Diagnostic standards and classification of tuberculosis in adults and children.Am J Respir Crit Care Med. 2000; 161: 1376-1395
- NRAMP1 genetic polymorphisms as a risk factor of tuberculous pleurisy.Int J Tuberc Lung Dis. 2003; 7: 370-375
- Association of vitamin D receptor genotype with leprosy type.J Infect Dis. 1999; 179: 187-191
- International consortium SN(i)Ps away at individuality.Lancet. 1999; 353: 1684
- Reading bits of genetic information: methods for single-nucleotide polymorphism analysis.Genome Res. 1998; 8: 769-776
- Modification of enzymatically amplified DNA for the detection of point mutations.Nucleic Acids Res. 1989; 17: 3606
- Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies.Am J Epidemiol. 2009; 169: 505-514
- Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool ‘CubeX’.BMC Bioinformatics. 2007; 8: 428-436
- NRAMP1 and resistance to intracellular pathogens.in: Bellamy R. Susceptibility to infectious diseases. Cambridge University Press, Cambridge2004: 221-258
- SLC11A1 (NRAMP1) but not SLC11A2 (NRAMP2) polymorphisms are associated with susceptibility to tuberculosis in a high-incidence community in South Africa.Int J Tuberc Lung Dis. 2004; 8: 1464-1471
- The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the NRAMP1 gene.J Exp Med. 1995; 182: 655-666
- Localisation of Nramp1 in macrophages: modulation with activation and infection.J Cell Sci. 1998; 111: 2855-2866
- Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane.J Exp Med. 2000; 192: 1237-1248
- Nramp1 modifies the fusion of Salmonella typhimurium-containing vacuoles with cellular endomembranes in macrophages.J Biol Chem. 2002; 277: 2258-2265
- Effect of Nramp1 on bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in bone marrow-derived mouse macrophages.Cell Microbiol. 2002; 4: 541-556
- Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification.J Exp Med. 1998; 188: 351-364
- Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/NRAMP1/SLC11A1 gene story.Immunol Lett. 2003; 85: 197-203
- NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis.J Infect. 2003; 46: 215-220
- Evidence that genetic susceptibility to Mycobacterium tuberculosis in a Brazilian population is under oligogenic control: linkage study of the candidate genes NRAMP1 and TNFA.Tuber Lung Dis. 1997; 78: 35-45
- Association between SLC11A1 polymorphisms and susceptibility to different clinical forms of tuberculosis in the Peruvian population.Infect Genet Evol. 2006; 6: 361-367
Article info
Publication history
Identification
Copyright
User license
Elsevier user license |
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy